Company: PGEN
Filing Date: 2025-03-19
Form Type: 10-K
Source: 0001356090-25-000007
Chunk: 246

Company: PRECIGEN, INC.
Filing Date: 2025-03-19
Form: 10-K
Item: Item 12
Chunk 246
---
 these available-for-sale investments all contractually mature within one year.

Changes in market interest rates and bond yields cause certain investments to fall below their cost basis, resulting in unrealized losses on investments. 

7. Fair Value Measurements

The carrying amount of cash and cash equivalents, receivables, accounts payable, accrued compensation and benefits, and other accrued liabilities approximate fair value due to the short maturity of these instruments.

F-29

The following table presents the placement in the fair value hierarchy of financial assets and liabilities that are measured at fair value on a recurring basis as of December 31, 2024:Quoted Prices in Active Markets(Level 1)Significant Other Observable Inputs(Level 2)Significant Unobservable Inputs(Level 3)December 31,2024AssetsUnited States government debt securities$— $67,474 $— $67,474 Certificates of deposit— 851 — 851 Corporate Bonds— 68 — 68 Total Assets$— $68,393 $— $68,393 LiabilitiesWarrant liabilities - 2024 Warrants$— $— $50,537 $50,537 Total liabilities$— $— $50,537 $50,537 The following table presents the placement in the fair value hierarchy of financial assets that are measured at fair value on a recurring basis as of December 31, 2023:Quoted Prices in Active Markets(Level 1)Significant Other Observable Inputs(Level 2)Significant Unobservable Inputs(Level 3)December 31,2023AssetsUnited States government debt securities$— $51,671 $— $51,671 Certificates of deposit— 3,361 — 3,361 Corporate Bonds— 245 — 245 Total Assets$— $55,277 $— $55,277 The method used to estimate the fair value of the Level 2 short-term debt investments in the tables above is based on professional pricing sources for identical or comparable instruments, rather than direct observations of quoted prices in active markets.Warrant liabilitiesThe Warrant liabilities (as defined below) are comprised of outstanding warrants to purchase 52,666,669 shares of common stock, no par value per share at an exercise price of $0.75 per share issued in a private placement in December 2024. The Warrants were accounted for as liabilities as the Warrants provide the